VERV Investors Have Opportunity to Lead Verve Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
VERVVerve Therapeutics(VERV) GlobeNewswire News Room·2024-09-03 22:30

LOS ANGELES, Sept. 03, 2024 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Verve Therapeutics, Inc. (“Verve” or “the Company”) (NASDAQ: VERV) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company’s securities between August 9, 2022, and April 1, 2024, inclusive (the “Class Pe ...